{"success":true,"data":{"pressRelease":{"id":"176987","rtpr_id":"nGNXbjCMHc-20261022","ticker":"SCNX","exchange":"NASDAQ","all_tickers":["SCNX"],"title":"SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027","author":"Globe Newswire","published_at":"2026-10-22T12:05:00.181Z","article_body":"Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to\nApproximately $1.22 Million, Supported by Continued Arbli(™) Growth and the\nCommercial Launch of REZENOPY(™)\n\nTwo FDA-Approved Commercial Products Position Company for Continued Sequential\nRevenue Growth\n\nHigh Gross Margins and Established Commercial Infrastructure Provide Operating\nLeverage Potential as Company Targets Profitability in 2027\n\nCOMMACK, NY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today issued the following letter to shareholders.\n\nKey Commercial and Financial Achievements During the First Nine Months of 2026\n* 256% Sequential Revenue Growth: Reported preliminary, unaudited\nthird-quarter 2026 revenue of approximately $1.22 million, compared to\n$343,639 in the second quarter, reflecting accelerating commercial momentum\nfollowing the launch of the Scienture’s second commercial product.\n\n* Successful Launch of Second FDA-Approved Product: Commercially launched\nREZENOPY(™) in August 2026, with initial wholesale shipments contributing to\nthird-quarter revenue and establishing a second commercial revenue stream.\n\n* 74% Sequential Increase in Arbli(™) Wholesale Unit Sales: Continued to\ndrive commercial adoption and increasing wholesale demand for Arbli(™)\nduring the third quarter of 2026.\n\n* Expanded Institutional Adoption: Secured formulary additions for Arbli(™)\nat more than ten (10) leading U.S. pediatric academic medical centers,\nstrengthening the product's presence within important healthcare institutions.\n\n* Expanded REZENOPY(™) Distribution: Advanced commercialization through a\nstrategic distribution partnership focused on addiction treatment centers,\nbroadening the product's potential market reach.\n\n* High Gross Margin Profile: Reported gross margins of approximately 97.7% in\nthe second quarter of 2026, supporting the potential for meaningful operating\nleverage as revenue increases.\n\n* Broad Commercial Market Access: REZENOPY(™) GPO agreements provide access\nto more than 5,000 healthcare facilities, with commercial payer and government\naccess potentially reaching over 100 million covered lives, while Arbli(™)\ncontinues to expand its formulary placements and payer coverage, supporting\nbroader adoption of both products.\n\n* Strengthened Intellectual Property Portfolio: Secured U.S. patent protection\nfor REZENOPY(™) extending into 2041, complementing Arbli(™) patent\nprotection until 2041.\nDear Fellow Shareholders,\n\nThe first nine months of 2026 have marked a transformational period for\nScienture as we transitioned into a multi-product commercial pharmaceutical\ncompany, accelerated revenue growth, and expanded the market presence of our\ntwo FDA-approved products. We believe these achievements have established a\nstrong foundation for the next phase of our growth and represent meaningful\nprogress toward our objective of achieving profitability in 2027.\n\nOur preliminary, unaudited third-quarter 2026 revenue reached approximately\n$1.22 million, representing a 256% sequential increase over the second\nquarter. This performance was supported by continued commercial growth in\nArbli(™), including a 74% sequential increase in wholesale unit sales,\nalongside initial wholesale shipments of REZENOPY(™) following its August\n2026 commercial launch.\n\nImportantly, we believe this momentum is only beginning to reflect the\ncommercial potential of our expanding product portfolio. We believe the\ncontinued commercial traction of Arbli(™), combined with the early-stage\ncommercialization of REZENOPY(™), positions us well to deliver continued\nsequential revenue growth as both products scale.\n\nOver the past several quarters, we have invested in establishing the\ncommercial infrastructure necessary to support our products, including sales\nresources, wholesale distribution, institutional market access, and payer\nrelationships. As revenue increases, we believe this existing infrastructure,\ncombined with our historically high gross margins, provides an opportunity to\nmeaningfully improve operating performance without a proportionate increase in\nexpenses.\n\nBuilding Momentum Across Two FDA-Approved Commercial Products\n\nArbli(™) Continues to Expand Its Commercial Footprint\n\nArbli(™) (losartan potassium) Oral Suspension is the first and only\nFDA-approved, ready-to-use oral liquid formulation of losartan, addressing an\nestablished U.S. market representing approximately $218 million in annual\nsales and more than 73 million prescriptions, according to August 2026 IQVIA\ndata.\n\nThis mature market has long been dominated by oral solid (tablet) formulations\nfrom generic manufacturers, with the original branded product (Cozaar) now\nlargely genericized. The vast majority of prescriptions are tablets, leaving a\nmeaningful underserved segment of patients, particularly elderly individuals,\npediatric patients age six and older, and others with dysphagia or difficulty\nswallowing, who previously relied on inconsistent pharmacy compounding.\n\nArbli(™) addresses this unmet need through a standardized, FDA-approved oral\nliquid formulation that eliminates the variability associated with pharmacy\ncompounding while offering flexible dosing, convenient room-temperature\nstorage, and an approved 24-month shelf life. We believe these attributes\nprovide meaningful advantages for physicians, patients, and healthcare\ninstitutions seeking consistent and convenient treatment options.\n\nDuring the third quarter of 2026, Arbli(™) wholesale unit sales increased\n74% sequentially, reflecting continued progress in expanding commercial\ndemand. We have also secured the addition of Arbli(™) to the formularies of\nmore than ten (10) leading U.S. pediatric academic medical centers, an\nimportant milestone in establishing the product within key institutional\ntreatment settings.\n\nWe believe these developments provide a foundation for continued market share\ngains as we pursue additional formulary placements, broaden physician\nawareness, and expand patient access. Arbli(™) also benefits from U.S.\npatent protection extending into 2041, supporting its long-term commercial\npotential.\n\nREZENOPY(™) Establishes a Second Revenue Growth Opportunity\n\nThe commercial launch of REZENOPY(™) (naloxone hydrochloride) Nasal Spray 10\nmg in August 2026 represented another important milestone in Scienture's\nevolution into a multi-product commercial pharmaceutical company.\n\nAccording to IQVIA data (August 2026), the U.S. naloxone nasal spray market\nrepresents approximately $137 million in annual sales, with approximately 9\nmillion units sold annually, has historically been led by lower-dose products,\nincluding Narcan® 4 mg, alongside other approved formulations and generic\nalternatives. The ongoing opioid crisis, particularly the prevalence of potent\nsynthetic opioids such as fentanyl, continues to underscore the importance of\naccess to opioid overdose reversal treatments.\n\nREZENOPY(™) is the highest-dose FDA-approved naloxone nasal spray available\nin the United States, delivering 10 mg of naloxone in a single-use device for\nthe emergency treatment of known or suspected opioid overdose. The product\ncombines the established naloxone molecule and familiar nasal spray delivery\nmethod with a differentiated higher-dose formulation, providing an additional\ntreatment option for healthcare providers and emergency responders.\n\nThrough our collaboration with Summit Biosciences, a subsidiary of Kindeva\nDrug Delivery, Scienture holds exclusive U.S. commercialization rights to\nREZENOPY(™), supporting our strategy to establish a differentiated presence\nin the naloxone market.\n\nInitial wholesale shipments contributed to our third-quarter revenue growth,\nand we are focused on expanding distribution and adoption through our\nstrategic commercialization relationships, including channels serving\naddiction treatment centers and healthcare institutions.\n\nAs REZENOPY(™) progresses beyond its initial launch phase, we believe\nincreasing market access and product adoption can support continued revenue\ngrowth alongside Arbli(™). REZENOPY(™) also benefits from U.S. patent\nprotection extending into 2041, supporting its long-term commercial potential.\n\nHigh Gross Margins and Operating Leverage Support Our Path Toward\nProfitability\n\nBeyond our commercial achievements, we view one of the most compelling aspects\nof Scienture's business model as the potential for significant operating\nleverage as revenue scales.\n\nWe believe we have made meaningful progress in improving our financial\nperformance and operating cost structure. During the second quarter of 2026,\noperating expenses decreased approximately 41% to $3.0 million, compared to\n$5.2 million in the prior-year period. Our operating loss improved\napproximately 48% to $2.7 million, compared to $5.2 million in the second\nquarter of 2025, while net loss narrowed approximately 58% to $2.8 million,\ncompared to $6.7 million in the prior-year period.\n\nImportantly, we reported gross margins of approximately 97.7% during the\nsecond quarter of 2026, demonstrating the attractive economics of our\ncommercial product portfolio. We believe these historically high gross\nmargins, combined with continued revenue growth and disciplined expense\nmanagement, provide an opportunity to further reduce operating losses as sales\nscale.\n\nWe have already established much of the commercial infrastructure required to\nsupport both products, including national sales resources, wholesale\ndistribution relationships, and institutional market access. As sales volumes\nincrease, we believe we can leverage these existing capabilities without a\nproportionate increase in operating expenses.\n\nOur focus remains on maximizing the revenue potential of the commercial\nplatform we have built while maintaining financial discipline. We believe the\ncombination of accelerating revenue growth, high gross margins, and an\nimproved operating cost structure positions Scienture to make meaningful\nprogress toward our objective of achieving profitability in 2027.\n\nExpanding Market Access and Strengthening Our Commercial Platform\n\nA key component of our strategy has been establishing the distribution and\nmarket access capabilities necessary to support sustained commercial growth of\nboth Arbli(™) and REZENOPY(™).\n\nFor REZENOPY(™), group purchasing organization (“GPO”) agreements\nprovide access to more than 5,000 healthcare facilities, while commercial\npayer coverage and government access through CMS have the potential to reach\nmore than 100 million covered lives.\n\nArbli(™) also continues to gain commercial traction, with wholesale unit\nsales increasing 74% sequentially in the third quarter. We secured additional\nformulary placements, expanded commercial access, and built on prior GPO and\npayer coverage wins, including expansions reaching approximately 12.5 million\nadditional covered lives.\n\nTogether, these developments, supported by our national sales resources and\nwholesale distribution capabilities, strengthen our commercial platform. We\nbelieve this infrastructure will enable us to scale revenue more efficiently,\nimprove operating leverage, and support our goal of achieving profitability in\n2027.\n\nCompetitive Advantages Position Scienture for Continued Market Share Gains\n\nWe believe Scienture is well positioned to capture market share in established\npharmaceutical markets through a combination of differentiated FDA-approved\nproducts, long-term intellectual property protection, and an established\ncommercial infrastructure.\n\nOur competitive advantage is built on three key strengths: differentiated\n505(b)(2)-style formulations that address unmet patient needs within large,\nestablished markets; U.S. patent protection extending into 2041 for Arbli(™)\nand REZENOPY(™); and a focused commercial platform encompassing national\nsales resources, GPO and payer relationships, wholesale distribution,\ninstitutional formulary access, and patient support capabilities.\n\nOur strategy for increasing market share centers on expanding institutional\nand hospital formulary adoption, broadening payer coverage, strengthening\nphysician engagement, and increasing product utilization across retail and\ninstitutional channels. We believe these initiatives will help drive continued\nsequential sales growth while leveraging our existing commercial\ninfrastructure.\n\nImportantly, both products address established markets with meaningful\nopportunities for penetration. Even modest market share gains within the\napproximately $218 million U.S. losartan market, combined with increasing\nadoption in the approximately $137million naloxone nasal spray market, could\ntranslate into meaningful incremental revenue. Given our historically high\ngross margins, we believe these opportunities can contribute significantly to\nimproving operating performance as sales scale.\n\nEarly commercial results, including the 74% sequential increase in Arbli(™)\nwholesale unit sales and initial REZENOPY(™) revenue contributions,\nreinforce our confidence in this strategy.\n\nLooking Ahead: Continued Revenue Growth and Profitability in 2027\n\nAs we move through the remainder of 2026 and into 2027, our priorities remain\ncentered on accelerating revenue growth, expanding commercial adoption, and\nimproving operating performance.\n\nFor Arbli(™), we intend to build on recent institutional formulary wins,\nbroaden physician engagement, and increase patient access across pediatric and\ncardiovascular treatment settings.\n\nFor REZENOPY(™), our focus is on expanding distribution, increasing\ninstitutional and treatment-center adoption, and building upon the initial\ncommercial revenue generated following its launch.\n\nWe believe the combination of these initiatives positions Scienture to sustain\nsequential revenue growth as both products continue to scale. Our historically\nhigh gross margins and established commercial infrastructure provide the\npotential for meaningful operating leverage as sales increase, supporting our\nobjective of achieving profitability in 2027.\n\nPositioned for the Next Phase of Growth\n\nScienture today is a fundamentally different company than it was at the\nbeginning of 2026. We have two FDA-approved products generating commercial\nrevenue, expanding institutional adoption, established distribution and market\naccess capabilities, and a high-margin business model designed to benefit from\nincreasing sales volumes.\n\nWe believe the next phase of our growth will be defined by our ability to\ntranslate these commercial achievements into sustained revenue growth,\nimproving financial performance, and ultimately profitability.\n\nWhile meaningful work remains ahead, we are encouraged by the progress we have\nmade and confident in the opportunities before us. Our focus remains on\ndisciplined execution, responsible capital allocation, and building a\nsustainable specialty pharmaceutical company capable of delivering long-term\nshareholder value.\n\nWe thank our shareholders for their continued confidence and support and look\nforward to providing additional updates as we advance our commercial and\nfinancial objectives.\n\nSincerely,\n\nNarasimhan Mani\nPresident and Co-Chief Executive Officer\n\nShankar Hariharan\nExecutive Chairman and Co-Chief Executive Officer\n\nAbout Arbli(™)\n\nArbli(™) is a novel proprietary formulation of losartan, a widely prescribed\nangiotensin receptor blocker (ARB) for hypertension. It is the first and only\nliquid formulation of losartan on the market that does not require compounding\nand has reduced dosing volume and long-term shelf life at room temperature\nstorage. Arbli(™) is FDA-approved for the treatment of hypertension in\npatients greater than six years old, for reducing the risk of stroke in\npatients with hypertension and left ventricular hypertrophy, and for treating\ndiabetic nephropathy in certain patients with type 2 diabetes. By offering a\nsafe, effective, and convenient liquid alternative, Arbli(™) provides a\ntailored solution for patients who require or prefer a liquid formulation. As\nan FDA-approved product, Arbli(™) provides consistent quality and dosing\naccuracy, addressing the risks and inconsistencies often associated with\nextemporaneously compounded losartan prescriptions. Arbli(™) has two issued\npatents from the USPTO, which are also listed in the FDA Orangebook.\n\nArbli(™) is the first and only oral liquid formulation of losartan approved\nby the U.S. FDA. Arbli(™) comes in a 165 mL bottle as a peppermint flavored\nsuspension that does not require refrigeration and has been approved for a\nshelf life of 24 months from the date of manufacture when stored at room\ntemperature.\n\nINDICATION\n\nArbli(™) is an angiotensin II receptor blocker (ARB) indicated for:\n* Treatment of hypertension, to lower blood pressure in adults and children\ngreater than 6 years old. Lowering blood pressure reduces the risk of fatal\nand nonfatal cardiovascular events, primarily strokes and myocardial\ninfarctions.\n\n* Reduction of the risk of stroke in patients with hypertension and left\nventricular hypertrophy.\n\n* Treatment of diabetic nephropathy with an elevated serum creatinine and\nproteinuria in patients with type 2 diabetes and a history of hypertension.\nIMPORTANT SAFETY INFORMATION\n* Do not take Arbli(™) when pregnant. When pregnancy is detected,\ndiscontinue Arbli(™) as soon as possible. Drugs that act directly on the\nrenin-angiotensin system can cause injury and death to the developing fetus.\nArbli(™) can cause fetal harm when administered to a pregnant woman. Use of\ndrugs that act on the renin-angiotensin system during the second and third\ntrimesters of pregnancy reduces fetal renal function and increases fetal and\nneonatal morbidity and death.\n\n* Do not co-administer Arbli(™) with aliskiren in patients with diabetes.\nAvoid use of aliskiren with Arbli(™) in patients with renal impairment (GFR\n<60 mL/min).\n\n* Do not administer Arbli(™) in patients with severe hepatic impairment.\nArbli(™) has not been studied in patients with severe hepatic impairment.\n\n* The most common adverse reactions are (incidence ≥2% and greater than\nplacebo): dizziness, upper respiratory infection, nasal congestion, and back\npain.\nYou are encouraged to report negative side effects of prescription drugs to\nthe FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also\ncontact Scienture at 1-833-754-4917.\n\nPlease see the full Prescribing Information for complete product information.\nFor more information, talk to your healthcare provider.\n\nAbout Hypertension\n\nHypertension (high blood pressure) is a cardiovascular condition, when the\npressure in the blood vessels is too high (140/90 mmHg or higher). According\nto the CDC, hypertension, or high blood pressure, affects nearly half of\nadults in the United States, or approximately 119.9 million people.\nHypertension is defined as a systolic blood pressure of 140 mmHg or higher,\nand diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk\nfactor for stroke and heart disease, which are leading causes of death in the\nU.S. Factors that increase the risk of having high blood pressure include:\nolder age, genetics, being overweight or obese, not being physically active,\nhigh-salt diet and drinking too much alcohol. Hypertension is clinically\ndiagnosed if, when blood pressure is measured on two different days, the\nsystolic blood pressure readings on both days is ≥140 mmHg and/or the\ndiastolic blood pressure readings on both days is ≥ 90 mmHg.\n\nAbout REZENOPY(™)\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10mg, is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present.\n\nREZENOPY(™) nasal spray is for intranasal use only and is supplied as a\ncarton containing two (2) blister packages each with a single spray device.\n\nIMPORTANT SAFETY INFORMATION\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present\nand is not a substitute for emergency medical care.\n\nImportant Safety Information\n* Contraindications: REZENOPY(™) nasal spray is contraindicated in patients\nknown to be hypersensitive to naloxone hydrochloride or to any of the other\ningredients.\n\n* Warnings and Precautions:\n * Risk of Recurrent Respiratory and CNS Depression: Due to the duration of\naction of naloxone relative to the opioid, keep the patient under continued\nsurveillance and administer additional doses as necessary while awaiting\nemergency medical assistance.\n\n* Risk of Limited Efficacy with Partial Agonists or Mixed\nAgonists/Antagonists: Reversal of respiratory depression caused by partial\nagonists or mixed agonists/antagonists, such as buprenorphine and pentazocine,\nmay be incomplete. Larger or repeat doses may be required.\n\n* Precipitation of Severe Opioid Withdrawal: Use in patients who are\nopioid-dependent may precipitate opioid withdrawal. In neonates, opioid\nwithdrawal may be life-threatening if not recognized and properly treated.\nMonitor for the development of opioid withdrawal.\n\n* Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid\ndepression may result in adverse cardiovascular effects. These events have\nprimarily occurred in patients who had pre-existing cardiovascular disorders\nor received other drugs that may have similar adverse cardiovascular effects.\nMonitor these patients closely in an appropriate healthcare setting after use\nof naloxone hydrochloride.\n\n \n* Adverse Reactions: The following adverse reactions were observed in a\nREZENOPY(™) nasal spray clinical study: upper abdominal pain,\nnasopharyngitis, and dysgeusia.\nFor complete product information, including Patient Information, please refer\nto the full Prescribing Information.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the products we may launch, the success those products\nmay have in the marketplace, such as Arbli(™) and REZENOPY(™), and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on the Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbjCMHc-20261022","title":"SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027","author":"Globe Newswire","ticker":"SCNX","created":"2026-10-22T12:05:00.181Z","tickers":["SCNX"],"exchange":"NASDAQ","article_body":"Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to\nApproximately $1.22 Million, Supported by Continued Arbli(™) Growth and the\nCommercial Launch of REZENOPY(™)\n\nTwo FDA-Approved Commercial Products Position Company for Continued Sequential\nRevenue Growth\n\nHigh Gross Margins and Established Commercial Infrastructure Provide Operating\nLeverage Potential as Company Targets Profitability in 2027\n\nCOMMACK, NY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today issued the following letter to shareholders.\n\nKey Commercial and Financial Achievements During the First Nine Months of 2026\n* 256% Sequential Revenue Growth: Reported preliminary, unaudited\nthird-quarter 2026 revenue of approximately $1.22 million, compared to\n$343,639 in the second quarter, reflecting accelerating commercial momentum\nfollowing the launch of the Scienture’s second commercial product.\n\n* Successful Launch of Second FDA-Approved Product: Commercially launched\nREZENOPY(™) in August 2026, with initial wholesale shipments contributing to\nthird-quarter revenue and establishing a second commercial revenue stream.\n\n* 74% Sequential Increase in Arbli(™) Wholesale Unit Sales: Continued to\ndrive commercial adoption and increasing wholesale demand for Arbli(™)\nduring the third quarter of 2026.\n\n* Expanded Institutional Adoption: Secured formulary additions for Arbli(™)\nat more than ten (10) leading U.S. pediatric academic medical centers,\nstrengthening the product's presence within important healthcare institutions.\n\n* Expanded REZENOPY(™) Distribution: Advanced commercialization through a\nstrategic distribution partnership focused on addiction treatment centers,\nbroadening the product's potential market reach.\n\n* High Gross Margin Profile: Reported gross margins of approximately 97.7% in\nthe second quarter of 2026, supporting the potential for meaningful operating\nleverage as revenue increases.\n\n* Broad Commercial Market Access: REZENOPY(™) GPO agreements provide access\nto more than 5,000 healthcare facilities, with commercial payer and government\naccess potentially reaching over 100 million covered lives, while Arbli(™)\ncontinues to expand its formulary placements and payer coverage, supporting\nbroader adoption of both products.\n\n* Strengthened Intellectual Property Portfolio: Secured U.S. patent protection\nfor REZENOPY(™) extending into 2041, complementing Arbli(™) patent\nprotection until 2041.\nDear Fellow Shareholders,\n\nThe first nine months of 2026 have marked a transformational period for\nScienture as we transitioned into a multi-product commercial pharmaceutical\ncompany, accelerated revenue growth, and expanded the market presence of our\ntwo FDA-approved products. We believe these achievements have established a\nstrong foundation for the next phase of our growth and represent meaningful\nprogress toward our objective of achieving profitability in 2027.\n\nOur preliminary, unaudited third-quarter 2026 revenue reached approximately\n$1.22 million, representing a 256% sequential increase over the second\nquarter. This performance was supported by continued commercial growth in\nArbli(™), including a 74% sequential increase in wholesale unit sales,\nalongside initial wholesale shipments of REZENOPY(™) following its August\n2026 commercial launch.\n\nImportantly, we believe this momentum is only beginning to reflect the\ncommercial potential of our expanding product portfolio. We believe the\ncontinued commercial traction of Arbli(™), combined with the early-stage\ncommercialization of REZENOPY(™), positions us well to deliver continued\nsequential revenue growth as both products scale.\n\nOver the past several quarters, we have invested in establishing the\ncommercial infrastructure necessary to support our products, including sales\nresources, wholesale distribution, institutional market access, and payer\nrelationships. As revenue increases, we believe this existing infrastructure,\ncombined with our historically high gross margins, provides an opportunity to\nmeaningfully improve operating performance without a proportionate increase in\nexpenses.\n\nBuilding Momentum Across Two FDA-Approved Commercial Products\n\nArbli(™) Continues to Expand Its Commercial Footprint\n\nArbli(™) (losartan potassium) Oral Suspension is the first and only\nFDA-approved, ready-to-use oral liquid formulation of losartan, addressing an\nestablished U.S. market representing approximately $218 million in annual\nsales and more than 73 million prescriptions, according to August 2026 IQVIA\ndata.\n\nThis mature market has long been dominated by oral solid (tablet) formulations\nfrom generic manufacturers, with the original branded product (Cozaar) now\nlargely genericized. The vast majority of prescriptions are tablets, leaving a\nmeaningful underserved segment of patients, particularly elderly individuals,\npediatric patients age six and older, and others with dysphagia or difficulty\nswallowing, who previously relied on inconsistent pharmacy compounding.\n\nArbli(™) addresses this unmet need through a standardized, FDA-approved oral\nliquid formulation that eliminates the variability associated with pharmacy\ncompounding while offering flexible dosing, convenient room-temperature\nstorage, and an approved 24-month shelf life. We believe these attributes\nprovide meaningful advantages for physicians, patients, and healthcare\ninstitutions seeking consistent and convenient treatment options.\n\nDuring the third quarter of 2026, Arbli(™) wholesale unit sales increased\n74% sequentially, reflecting continued progress in expanding commercial\ndemand. We have also secured the addition of Arbli(™) to the formularies of\nmore than ten (10) leading U.S. pediatric academic medical centers, an\nimportant milestone in establishing the product within key institutional\ntreatment settings.\n\nWe believe these developments provide a foundation for continued market share\ngains as we pursue additional formulary placements, broaden physician\nawareness, and expand patient access. Arbli(™) also benefits from U.S.\npatent protection extending into 2041, supporting its long-term commercial\npotential.\n\nREZENOPY(™) Establishes a Second Revenue Growth Opportunity\n\nThe commercial launch of REZENOPY(™) (naloxone hydrochloride) Nasal Spray 10\nmg in August 2026 represented another important milestone in Scienture's\nevolution into a multi-product commercial pharmaceutical company.\n\nAccording to IQVIA data (August 2026), the U.S. naloxone nasal spray market\nrepresents approximately $137 million in annual sales, with approximately 9\nmillion units sold annually, has historically been led by lower-dose products,\nincluding Narcan® 4 mg, alongside other approved formulations and generic\nalternatives. The ongoing opioid crisis, particularly the prevalence of potent\nsynthetic opioids such as fentanyl, continues to underscore the importance of\naccess to opioid overdose reversal treatments.\n\nREZENOPY(™) is the highest-dose FDA-approved naloxone nasal spray available\nin the United States, delivering 10 mg of naloxone in a single-use device for\nthe emergency treatment of known or suspected opioid overdose. The product\ncombines the established naloxone molecule and familiar nasal spray delivery\nmethod with a differentiated higher-dose formulation, providing an additional\ntreatment option for healthcare providers and emergency responders.\n\nThrough our collaboration with Summit Biosciences, a subsidiary of Kindeva\nDrug Delivery, Scienture holds exclusive U.S. commercialization rights to\nREZENOPY(™), supporting our strategy to establish a differentiated presence\nin the naloxone market.\n\nInitial wholesale shipments contributed to our third-quarter revenue growth,\nand we are focused on expanding distribution and adoption through our\nstrategic commercialization relationships, including channels serving\naddiction treatment centers and healthcare institutions.\n\nAs REZENOPY(™) progresses beyond its initial launch phase, we believe\nincreasing market access and product adoption can support continued revenue\ngrowth alongside Arbli(™). REZENOPY(™) also benefits from U.S. patent\nprotection extending into 2041, supporting its long-term commercial potential.\n\nHigh Gross Margins and Operating Leverage Support Our Path Toward\nProfitability\n\nBeyond our commercial achievements, we view one of the most compelling aspects\nof Scienture's business model as the potential for significant operating\nleverage as revenue scales.\n\nWe believe we have made meaningful progress in improving our financial\nperformance and operating cost structure. During the second quarter of 2026,\noperating expenses decreased approximately 41% to $3.0 million, compared to\n$5.2 million in the prior-year period. Our operating loss improved\napproximately 48% to $2.7 million, compared to $5.2 million in the second\nquarter of 2025, while net loss narrowed approximately 58% to $2.8 million,\ncompared to $6.7 million in the prior-year period.\n\nImportantly, we reported gross margins of approximately 97.7% during the\nsecond quarter of 2026, demonstrating the attractive economics of our\ncommercial product portfolio. We believe these historically high gross\nmargins, combined with continued revenue growth and disciplined expense\nmanagement, provide an opportunity to further reduce operating losses as sales\nscale.\n\nWe have already established much of the commercial infrastructure required to\nsupport both products, including national sales resources, wholesale\ndistribution relationships, and institutional market access. As sales volumes\nincrease, we believe we can leverage these existing capabilities without a\nproportionate increase in operating expenses.\n\nOur focus remains on maximizing the revenue potential of the commercial\nplatform we have built while maintaining financial discipline. We believe the\ncombination of accelerating revenue growth, high gross margins, and an\nimproved operating cost structure positions Scienture to make meaningful\nprogress toward our objective of achieving profitability in 2027.\n\nExpanding Market Access and Strengthening Our Commercial Platform\n\nA key component of our strategy has been establishing the distribution and\nmarket access capabilities necessary to support sustained commercial growth of\nboth Arbli(™) and REZENOPY(™).\n\nFor REZENOPY(™), group purchasing organization (“GPO”) agreements\nprovide access to more than 5,000 healthcare facilities, while commercial\npayer coverage and government access through CMS have the potential to reach\nmore than 100 million covered lives.\n\nArbli(™) also continues to gain commercial traction, with wholesale unit\nsales increasing 74% sequentially in the third quarter. We secured additional\nformulary placements, expanded commercial access, and built on prior GPO and\npayer coverage wins, including expansions reaching approximately 12.5 million\nadditional covered lives.\n\nTogether, these developments, supported by our national sales resources and\nwholesale distribution capabilities, strengthen our commercial platform. We\nbelieve this infrastructure will enable us to scale revenue more efficiently,\nimprove operating leverage, and support our goal of achieving profitability in\n2027.\n\nCompetitive Advantages Position Scienture for Continued Market Share Gains\n\nWe believe Scienture is well positioned to capture market share in established\npharmaceutical markets through a combination of differentiated FDA-approved\nproducts, long-term intellectual property protection, and an established\ncommercial infrastructure.\n\nOur competitive advantage is built on three key strengths: differentiated\n505(b)(2)-style formulations that address unmet patient needs within large,\nestablished markets; U.S. patent protection extending into 2041 for Arbli(™)\nand REZENOPY(™); and a focused commercial platform encompassing national\nsales resources, GPO and payer relationships, wholesale distribution,\ninstitutional formulary access, and patient support capabilities.\n\nOur strategy for increasing market share centers on expanding institutional\nand hospital formulary adoption, broadening payer coverage, strengthening\nphysician engagement, and increasing product utilization across retail and\ninstitutional channels. We believe these initiatives will help drive continued\nsequential sales growth while leveraging our existing commercial\ninfrastructure.\n\nImportantly, both products address established markets with meaningful\nopportunities for penetration. Even modest market share gains within the\napproximately $218 million U.S. losartan market, combined with increasing\nadoption in the approximately $137million naloxone nasal spray market, could\ntranslate into meaningful incremental revenue. Given our historically high\ngross margins, we believe these opportunities can contribute significantly to\nimproving operating performance as sales scale.\n\nEarly commercial results, including the 74% sequential increase in Arbli(™)\nwholesale unit sales and initial REZENOPY(™) revenue contributions,\nreinforce our confidence in this strategy.\n\nLooking Ahead: Continued Revenue Growth and Profitability in 2027\n\nAs we move through the remainder of 2026 and into 2027, our priorities remain\ncentered on accelerating revenue growth, expanding commercial adoption, and\nimproving operating performance.\n\nFor Arbli(™), we intend to build on recent institutional formulary wins,\nbroaden physician engagement, and increase patient access across pediatric and\ncardiovascular treatment settings.\n\nFor REZENOPY(™), our focus is on expanding distribution, increasing\ninstitutional and treatment-center adoption, and building upon the initial\ncommercial revenue generated following its launch.\n\nWe believe the combination of these initiatives positions Scienture to sustain\nsequential revenue growth as both products continue to scale. Our historically\nhigh gross margins and established commercial infrastructure provide the\npotential for meaningful operating leverage as sales increase, supporting our\nobjective of achieving profitability in 2027.\n\nPositioned for the Next Phase of Growth\n\nScienture today is a fundamentally different company than it was at the\nbeginning of 2026. We have two FDA-approved products generating commercial\nrevenue, expanding institutional adoption, established distribution and market\naccess capabilities, and a high-margin business model designed to benefit from\nincreasing sales volumes.\n\nWe believe the next phase of our growth will be defined by our ability to\ntranslate these commercial achievements into sustained revenue growth,\nimproving financial performance, and ultimately profitability.\n\nWhile meaningful work remains ahead, we are encouraged by the progress we have\nmade and confident in the opportunities before us. Our focus remains on\ndisciplined execution, responsible capital allocation, and building a\nsustainable specialty pharmaceutical company capable of delivering long-term\nshareholder value.\n\nWe thank our shareholders for their continued confidence and support and look\nforward to providing additional updates as we advance our commercial and\nfinancial objectives.\n\nSincerely,\n\nNarasimhan Mani\nPresident and Co-Chief Executive Officer\n\nShankar Hariharan\nExecutive Chairman and Co-Chief Executive Officer\n\nAbout Arbli(™)\n\nArbli(™) is a novel proprietary formulation of losartan, a widely prescribed\nangiotensin receptor blocker (ARB) for hypertension. It is the first and only\nliquid formulation of losartan on the market that does not require compounding\nand has reduced dosing volume and long-term shelf life at room temperature\nstorage. Arbli(™) is FDA-approved for the treatment of hypertension in\npatients greater than six years old, for reducing the risk of stroke in\npatients with hypertension and left ventricular hypertrophy, and for treating\ndiabetic nephropathy in certain patients with type 2 diabetes. By offering a\nsafe, effective, and convenient liquid alternative, Arbli(™) provides a\ntailored solution for patients who require or prefer a liquid formulation. As\nan FDA-approved product, Arbli(™) provides consistent quality and dosing\naccuracy, addressing the risks and inconsistencies often associated with\nextemporaneously compounded losartan prescriptions. Arbli(™) has two issued\npatents from the USPTO, which are also listed in the FDA Orangebook.\n\nArbli(™) is the first and only oral liquid formulation of losartan approved\nby the U.S. FDA. Arbli(™) comes in a 165 mL bottle as a peppermint flavored\nsuspension that does not require refrigeration and has been approved for a\nshelf life of 24 months from the date of manufacture when stored at room\ntemperature.\n\nINDICATION\n\nArbli(™) is an angiotensin II receptor blocker (ARB) indicated for:\n* Treatment of hypertension, to lower blood pressure in adults and children\ngreater than 6 years old. Lowering blood pressure reduces the risk of fatal\nand nonfatal cardiovascular events, primarily strokes and myocardial\ninfarctions.\n\n* Reduction of the risk of stroke in patients with hypertension and left\nventricular hypertrophy.\n\n* Treatment of diabetic nephropathy with an elevated serum creatinine and\nproteinuria in patients with type 2 diabetes and a history of hypertension.\nIMPORTANT SAFETY INFORMATION\n* Do not take Arbli(™) when pregnant. When pregnancy is detected,\ndiscontinue Arbli(™) as soon as possible. Drugs that act directly on the\nrenin-angiotensin system can cause injury and death to the developing fetus.\nArbli(™) can cause fetal harm when administered to a pregnant woman. Use of\ndrugs that act on the renin-angiotensin system during the second and third\ntrimesters of pregnancy reduces fetal renal function and increases fetal and\nneonatal morbidity and death.\n\n* Do not co-administer Arbli(™) with aliskiren in patients with diabetes.\nAvoid use of aliskiren with Arbli(™) in patients with renal impairment (GFR\n<60 mL/min).\n\n* Do not administer Arbli(™) in patients with severe hepatic impairment.\nArbli(™) has not been studied in patients with severe hepatic impairment.\n\n* The most common adverse reactions are (incidence ≥2% and greater than\nplacebo): dizziness, upper respiratory infection, nasal congestion, and back\npain.\nYou are encouraged to report negative side effects of prescription drugs to\nthe FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also\ncontact Scienture at 1-833-754-4917.\n\nPlease see the full Prescribing Information for complete product information.\nFor more information, talk to your healthcare provider.\n\nAbout Hypertension\n\nHypertension (high blood pressure) is a cardiovascular condition, when the\npressure in the blood vessels is too high (140/90 mmHg or higher). According\nto the CDC, hypertension, or high blood pressure, affects nearly half of\nadults in the United States, or approximately 119.9 million people.\nHypertension is defined as a systolic blood pressure of 140 mmHg or higher,\nand diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk\nfactor for stroke and heart disease, which are leading causes of death in the\nU.S. Factors that increase the risk of having high blood pressure include:\nolder age, genetics, being overweight or obese, not being physically active,\nhigh-salt diet and drinking too much alcohol. Hypertension is clinically\ndiagnosed if, when blood pressure is measured on two different days, the\nsystolic blood pressure readings on both days is ≥140 mmHg and/or the\ndiastolic blood pressure readings on both days is ≥ 90 mmHg.\n\nAbout REZENOPY(™)\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10mg, is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present.\n\nREZENOPY(™) nasal spray is for intranasal use only and is supplied as a\ncarton containing two (2) blister packages each with a single spray device.\n\nIMPORTANT SAFETY INFORMATION\n\nREZENOPY(™) (naloxone hydrochloride) Nasal Spray 10 mg is an opioid\nantagonist indicated for the emergency treatment of known or suspected opioid\noverdose, as manifested by respiratory and/or central nervous system\ndepression in adult and pediatric patients. It is intended for immediate\nadministration as emergency therapy in settings where opioids may be present\nand is not a substitute for emergency medical care.\n\nImportant Safety Information\n* Contraindications: REZENOPY(™) nasal spray is contraindicated in patients\nknown to be hypersensitive to naloxone hydrochloride or to any of the other\ningredients.\n\n* Warnings and Precautions:\n * Risk of Recurrent Respiratory and CNS Depression: Due to the duration of\naction of naloxone relative to the opioid, keep the patient under continued\nsurveillance and administer additional doses as necessary while awaiting\nemergency medical assistance.\n\n* Risk of Limited Efficacy with Partial Agonists or Mixed\nAgonists/Antagonists: Reversal of respiratory depression caused by partial\nagonists or mixed agonists/antagonists, such as buprenorphine and pentazocine,\nmay be incomplete. Larger or repeat doses may be required.\n\n* Precipitation of Severe Opioid Withdrawal: Use in patients who are\nopioid-dependent may precipitate opioid withdrawal. In neonates, opioid\nwithdrawal may be life-threatening if not recognized and properly treated.\nMonitor for the development of opioid withdrawal.\n\n* Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid\ndepression may result in adverse cardiovascular effects. These events have\nprimarily occurred in patients who had pre-existing cardiovascular disorders\nor received other drugs that may have similar adverse cardiovascular effects.\nMonitor these patients closely in an appropriate healthcare setting after use\nof naloxone hydrochloride.\n\n \n* Adverse Reactions: The following adverse reactions were observed in a\nREZENOPY(™) nasal spray clinical study: upper abdominal pain,\nnasopharyngitis, and dysgeusia.\nFor complete product information, including Patient Information, please refer\nto the full Prescribing Information.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the products we may launch, the success those products\nmay have in the marketplace, such as Arbli(™) and REZENOPY(™), and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on the Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-22T12:05:00.222582426Z","server_sent_at_ms":1792670700222},"received_at":"2026-10-22T12:05:00.430Z","source_url":null},"analysis":{"id":"164950","press_release_id":"176987","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Revenue base is very small (~$1.22M in Q3) — 256% sequential growth is off a tiny denominator","All Q3 figures are preliminary and unaudited","Company still operating at a loss (~$2.8M quarterly net loss)","Forward-looking statements flag going concern risk and potential dilution from future funding","Nasdaq listing maintenance risk disclosed in forward-looking statements"],"eventType":"earnings","narrative":"Scienture Holdings issued a shareholder letter reporting preliminary unaudited Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase over Q2's $343,639.\n\nGrowth was driven by a 74% sequential increase in Arbli wholesale unit sales plus initial wholesale shipments of REZENOPY, launched in August 2026 as the company's second FDA-approved product.\n\nQ2 2026 gross margins were approximately 97.7%, with net loss narrowed 58% year-over-year to $2.8 million; management targets profitability in 2027 on operating leverage.\n\nRevenue remains small in absolute terms, and all headline figures are preliminary and unaudited, so execution risk on the 2027 profitability target is high.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap specialty pharma shows 256% sequential revenue growth with two FDA-approved products, but profitability target is still a year out and the revenue base is tiny."},"keyFigures":{"revenue":1220000,"guidance":"Continued sequential revenue growth and targeted profitability in 2027","revenueYoy":"not stated","customDimensions":{"q2_2026_revenue":343639,"q2_2026_net_loss":2800000,"arbli_market_size":"$218 million annual U.S. losartan market","gpo_facility_access":"5,000+ healthcare facilities","gross_margin_q2_2026":"97.7%","naloxone_market_size":"$137 million annual U.S. naloxone nasal spray market","net_loss_narrowing_yoy":"58%","q2_2026_operating_loss":2700000,"covered_lives_potential":"100 million+","sequential_revenue_growth":"256%","q2_2026_operating_expenses":3000000,"arbli_wholesale_unit_growth":"74%","operating_loss_improvement_yoy":"48%","operating_expense_reduction_yoy":"41%"}},"quotedText":"The first nine months of 2026 have marked a transformational period for Scienture as we transitioned into a multi-product commercial pharmaceutical company","namedEntities":{"people":[{"name":"Narasimhan Mani","role":"President and Co-CEO"},{"name":"Shankar Hariharan","role":"Executive Chairman and Co-CEO"}],"products":["Arbli (losartan potassium) Oral Suspension","REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg","Cozaar","Narcan"],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX","relationship":"filer"},{"name":"Summit Biosciences","relationship":"partner"},{"name":"Kindeva Drug Delivery","relationship":"partner (parent of Summit Biosciences)"}],"dollarAmounts":[{"amount":"$1.22 million","context":"preliminary unaudited Q3 2026 revenue"},{"amount":"$343,639","context":"Q2 2026 revenue"},{"amount":"$3.0 million","context":"Q2 2026 operating expenses"},{"amount":"$2.7 million","context":"Q2 2026 operating loss"},{"amount":"$2.8 million","context":"Q2 2026 net loss"},{"amount":"$218 million","context":"annual U.S. losartan market (IQVIA, Aug 2026)"},{"amount":"$137 million","context":"annual U.S. naloxone nasal spray market (IQVIA, Aug 2026)"}]},"materialImpact":{"score":3,"reasoning":"Preliminary Q3 revenue up 256% sequentially to ~$1.22M and second product launch (REZENOPY) are positive, but the absolute revenue base is tiny (~$1.2M) and figures are unaudited/preliminary from a shareholder letter rather than a formal earnings report."},"tickerRelevance":{"others":[],"primary":"SCNX"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":["product_launch","guidance_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"preliminary unaudited revenue update with strong sequential growth","householdBrandBoost":0,"retailFavoriteBoost":"low-moderate (small-cap biopharma with two commercial products)"}},"event_type":"earnings","event_type_secondary":["product_launch","guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Scienture Holdings issued a shareholder letter reporting preliminary unaudited Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase over Q2's $343,639.\n\nGrowth was driven by a 74% sequential increase in Arbli wholesale unit sales plus initial wholesale shipments of REZENOPY, launched in August 2026 as the company's second FDA-approved product.\n\nQ2 2026 gross margins were approximately 97.7%, with net loss narrowed 58% year-over-year to $2.8 million; management targets profitability in 2027 on operating leverage.\n\nRevenue remains small in absolute terms, and all headline figures are preliminary and unaudited, so execution risk on the 2027 profitability target is high.","key_figures":{"revenue":1220000,"guidance":"Continued sequential revenue growth and targeted profitability in 2027","revenueYoy":"not stated","customDimensions":{"q2_2026_revenue":343639,"q2_2026_net_loss":2800000,"arbli_market_size":"$218 million annual U.S. losartan market","gpo_facility_access":"5,000+ healthcare facilities","gross_margin_q2_2026":"97.7%","naloxone_market_size":"$137 million annual U.S. naloxone nasal spray market","net_loss_narrowing_yoy":"58%","q2_2026_operating_loss":2700000,"covered_lives_potential":"100 million+","sequential_revenue_growth":"256%","q2_2026_operating_expenses":3000000,"arbli_wholesale_unit_growth":"74%","operating_loss_improvement_yoy":"48%","operating_expense_reduction_yoy":"41%"}},"named_entities":{"people":[{"name":"Narasimhan Mani","role":"President and Co-CEO"},{"name":"Shankar Hariharan","role":"Executive Chairman and Co-CEO"}],"products":["Arbli (losartan potassium) Oral Suspension","REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg","Cozaar","Narcan"],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX","relationship":"filer"},{"name":"Summit Biosciences","relationship":"partner"},{"name":"Kindeva Drug Delivery","relationship":"partner (parent of Summit Biosciences)"}],"dollarAmounts":[{"amount":"$1.22 million","context":"preliminary unaudited Q3 2026 revenue"},{"amount":"$343,639","context":"Q2 2026 revenue"},{"amount":"$3.0 million","context":"Q2 2026 operating expenses"},{"amount":"$2.7 million","context":"Q2 2026 operating loss"},{"amount":"$2.8 million","context":"Q2 2026 net loss"},{"amount":"$218 million","context":"annual U.S. losartan market (IQVIA, Aug 2026)"},{"amount":"$137 million","context":"annual U.S. naloxone nasal spray market (IQVIA, Aug 2026)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T12:05:08.011Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"micro-cap","eventGravity":"preliminary unaudited revenue update with strong sequential growth","householdBrandBoost":0,"retailFavoriteBoost":"low-moderate (small-cap biopharma with two commercial products)"}},"durationMs":7496,"modelName":"glm-5.3-flashx"}}